Another large international retrospective cohort study that included 1236 breast cancer patients with germline BRCA1/2 mutations diagnosed at age ≤40 years examined clinical outcomes associated with each BRCA mutation type and hormone receptor (HR) status [224]. The gene discussed is NR4A1; the disease is breast cancer.